Tag: Secondary
-
Coronary spasm secondary to biphasic anaphylaxis after hymenoptera stings.
Related Articles Coronary spasm secondary to biphasic anaphylaxis after hymenoptera stings. Ann Allergy Asthma Immunol. 2016 Jun 1; Authors: Blasco-Navalpotro MÁ, Orejas-Gallego A, Flordelís-Lasierra JL, Prior-Gómez N, Jiménez-Jiménez J, Seoane-Leston FJ PMID: 27263087 [PubMed – as supplied by publisher] View full post on pubmed: asthma
-
Hypereosinophilic syndrome secondary to strongyloides infection: a case of recurrent asthma exacerbations.
Hypereosinophilic syndrome secondary to strongyloides infection: a case of recurrent asthma exacerbations. BMJ Case Rep. 2013;2013 Authors: Khan WA, Santhanakrishnan K Abstract Hypereosinophilic syndrome is a disease characterised by a persistently elevated eosinophil count. The syndrome can be reactive to infections, autoimmune disease, cancers, etc. Multiple organ involvement can occur including cardiomyopathies, pulmonary involvement and…
-
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … – RTT News
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In …RTT NewsArray BioPharma Inc. (ARRY: Quote) announced positive results from a placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary … View full post on asthma – Google News
-
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study – PR Newswire (press release)
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma StudyPR Newswire (press release)BOULDER, Colo., July 23, 2013 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced positive results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, …Array Biopharma To Report Top-line Results From ARRY-502 Asthma TrialBenzingaAfter-market Movers…